Astonea Labs commits $10K to launch US subsidiary Longevity Science
What's the deal? Astonea LabsDealroom has a profile for this one. Try Dealroom → has approved a $10,000 investment to incorporate Longevity Science, a wholly owned US subsidiary, its board disclosed in exchange filings on September 9, 2026. The move establishes a direct footprint in the North American pharmaceutical and wellness market.
What's the endgame? Longevity Science will operate as an international arm focused on health science and wellness products. The initial $10,000 covers entity formation, legal registration fees, and administrative setup in the US.
What changes for customers? A dedicated local presence gives North American distributors streamlined procurement, faster turnaround, and steadier supply of AstoneaDealroom has a profile for this one. Try Dealroom →'s formulations. It also lets the company handle export compliance and distribution partnerships more directly.
Why now? Astonea wants to capture higher-margin export contracts and cut out intermediaries. An overseas entity shortens supply chains and builds direct ties with North American nutraceutical and pharmaceutical brands.
The signal: Indian contract manufacturers are increasingly setting up direct international subsidiaries to bypass trade barriers and reach customers firsthand. Astonea's small but deliberate US bet fits that broader push to move up the export value chain.
Read more: wownews24x7.com
Image credit: Generated with Gemini
